Clinical trial

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04285580

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Bimatoprost SR Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record LUMIGAN Normalized identity: LumiganView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-06-11

PhasePHASE3

Conditions

Open-Angle Glaucomaverified · MONDO: open-angle glaucoma

Ocular Hypertensionverified · MONDO: ocular hypertension

Interventions

Bimatoprost SRDRUG

LUMIGANDRUG · verified · RxNorm: Lumigan

Sponsors & collaborators

AbbVielead sponsor

Mapped research locations

AustinTexas, United States1 Winston-SalemNorth Carolina, United States1 Newport BeachCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04285580 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.